Regeneron to highlight new and updated clinical data at asco showcasing breadth of cancer research

Oral presentations include interim results from pivotal trial of linvoseltamab (bcmaxcd3) in relapsed/refractory multiple myeloma and three cohorts of fianlimab (lag-3 inhibitor) combined with libtayo ® (cemiplimab-rwlc) in advanced melanoma
REGN Ratings Summary
REGN Quant Ranking